Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022
Notice Number:
NOT-OD-22-190

Key Dates

Release Date:

August 3, 2022

Related Announcements

RFA-DA-23-032 - NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)

RFA-DA-23-031 - NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)

RFA-DA-23-029 - NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

RFA-DA-23-028 - NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

RFA-DA-23-026 - NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)

RFA-DA-23-025 - NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed)

RFA-DA-23-024 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)

RFA-DA-23-023 - NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)

RFA-DA-23-013 - NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)

PAR-22-223 - Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed).

PAR-22-215 - Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)

RFA-NS-22-070 - HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain(R01 Clinical Trial Not Allowed).

RFA-NS-22-062 - Connecting Machine Readable Digital Human AD/ADRD Neuropathological Library Platforms for Advanced Analytics (U24 Clinical Trial Not Allowed).

RFA-AT-23-004 - REsearch Across Complementary and Integrative Health Institutions (REACH) Virtual Resource Centers (U24 Clinical Trial Not Allowed).

RFA-AG-23-020 - Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (UH2/UH3 Clinical Trial Not Allowed).

RFA-AG-23-027 - Resource Centers for Minority Aging Research (RCMAR) Coordinating Center (U24 Clinical Trial Optional)

RFA-AG-23-026 - Resource Centers for Minority Aging Research (RCMAR) (P30 Clinical Trial Optional)

RFA-AG-23-025 - Alzheimer's-related Resource Centers for Minority Aging Research (AD/ADRD RCMAR) (P30 Clinical Trial Optional).

PAR-22-222 - Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

PAR-22-205 - NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed

RFA-HD-23-012 - Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed)

PAR-22-221 - AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed)

Issued by

NATIONAL INSTITUTES OF HEALTH (NIH)

Agency for Healthcare Research and Quality (AHRQ)

Purpose

This notice informs the community of NIH and AHRQ application due date adjustments to accommodate scheduled federal system downtime. Grants.gov has a planned production system outage from Friday, September 23, 2022 at 12:01 AM ET to Thursday, September 29, 2022 at 11:59 PM ET (see Grants.gov calendar). Grants.gov will use this time to migrate their services to the Cloud.

In response, NIH and AHRQ due dates that fall on or between September 22 and September 30, 2022 will move to October 3, 2022.

The following caveats and considerations apply:

  • Applicants planning to submit to NIH under the Continuous Submission policy should consider this downtime when planning their submission. The Continuous Submission application receipt period end date for the September 7, 2022 AIDS application due date (January Advisory Council) remains Saturday, October 1, 2022 and therefore automatically moves forward to October 3, 2022.
  • The two-week window of consideration associated with the NIH Late Application Policy (when applicable) will be calculated from the original due dates.
  • The two-day application viewing window in eRA Commons will continue to function as normal for applications successfully submitted through Grants.gov. Applicants are reminded to Reject their application in eRA Commons, if a corrective submission is planned prior to the October 3 due date. Otherwise, it may be necessary to officially Withdraw Your Application to submit a changed/corrected application prior to the due date.
  • This notice serves as notification of the due date change for impacted funding opportunities. Edits to due dates within the text of individual funding opportunities will NOT be made.
    • NIH and AHRQ FOAs are posted with a grace period which allows applications to be submitted through Grants.gov systems even if the submission deadline shifts beyond the expiration date of the FOA. This allows us to rely on staff rather than systems to determine if an application will be accepted.
    • If you experience any issues with your submission following Grants.gov’s return to service (e.g., Grants.gov message indicating the opportunity is closed), please contact the eRA Service Desk for assistance.

Inquiries

Please direct all NIH inquiries to:
NIH Office of Policy for Extramural Research Administration (OPERA)
Systems Policy Branch
Email:OPERAsystemspolicy@nih.gov

Please direct all AHRQ inquiries to:

Kathryn Marron, Ph.D.
Agency for Healthcare Research and Quality (AHRQ)
Telephone: 301-427-1554
Email: Kathryn.Marron@ahrq.hhs.gov

Please direct all technical inquiries to:
eRA Service Desk

Submit a web ticket (preferred method):https://era.nih.gov/need-help

Toll-free: 1-866-504-9552
Phone: 301-402-7469